First COVID-19 vaccine approval brings Sputnik moment, but no Phase III data

11 August 2020
covid_big

Being able to boast that his country has produced the world’s first COVID-19 vaccine is just what Russian President Vladimir Putin ordered, but it remains to be seen how safe and effective the product is.

The two-dose adenovirus vaccine, which will be called Sputnik V in a throwback to the Soviet Union’s pioneering Cold War satellite program, has been developed by Moscow's Gamaleya Institute.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Pharmaceutical